Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom Disease): Results from a prospective, multicenter study over 66 weeks

Movement Disorders

Volumn 27, Issue 2, 2012, Pages 277-283

  García Borreguero, Diego ^a   Högl, Birgit ^b   Ferini Strambi, Luigi ^c   Winkelman, John ^d   Hill Zabala, Christina ^e   Asgharian, Afsaneh ^e   Allen, Richard ^f  

^a SLEEP RESEARCH INSTITUTE   (Spain)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e GLAXOSMITHKLINE   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Augmentation; Dopaminergic agents; Restless legs syndrome (RLS); RLS treatment; Ropinirole; Willis Ekbom disease

Indexed keywords

PLACEBO; ROPINIROLE; ROR 104836; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BACKACHE; CONTROLLED STUDY; DIARRHEA; DISEASE AUGMENTATION; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; INCIDENCE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESTLESS LEGS SYNDROME; RHINOPHARYNGITIS; SOMNOLENCE; STRUCTURED INTERVIEW; TREATMENT DURATION; VOMITING;

ADULT; AGED; ANTIPARKINSON AGENTS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RESTLESS LEGS SYNDROME; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84856960608     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.24889     Document Type: Article

References (21)

1. Silber MH, Ehrenberg BL, Allen RP, et al. An algorithm for the management of restless legs syndrome. Mayo Clin Proc. 2004; 79: 916-922.
2. Garcia-Borreguero D, Grunstein R, Sridhar G, et al. A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome. Sleep Med. 2007; 8: 742-752.
3. Montplaisir J, Karrasch J, Haan J, Volc D. Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial. Mov Disord. 2006; 21: 1627-1635.
4. Allen R, Becker PM, Bogan R, et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep. 2004; 27: 907-914.
5. Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry. 2004; 75: 92-97.
6. Trenkwalder C, Hening WA, Montagna P, et al. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord. 2008; 23: 2267-2302.
7. Walters AS, Ondo WG, Dreykluft T, Grunstein R, Lee D, Sethi K. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord. 2004; 19: 1414-1423.
8. Allen RP, Ondo W, Ball E, et al. Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample. Personal Communication.
9. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003; 4: 101-119.
10. Garcia-Borreguero D, Allen RP, Kohnen R, et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med. 2007; 8: 520-530.
11. Hening WA, Allen RP, Thanner S, et al. The Johns Hopkins telephone diagnostic interview for the restless legs syndrome: preliminary investigation for validation in a multi-center patient and control population. Sleep Med. 2003; 4: 137-141.
12. Walters AS, LeBrocq C, Dhar A, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. 2003; 4: 121-132.
13. Högl B, Garcia-Borreguero D, Gschliesser V, Cabrero B, Kohnen R, Allen RP. On the development of the "Structured Interview for Diagnosis of Augmentation during RLS treatment" (RLS-SIDA): first experiences. Sleep Med. 2005; 5: S158
14. Garcia-Borreguero D, Kohnen R, Hogl B, et al. Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome. Sleep Med. 2007; 8: 455-463.
15. Garcia-Borreguero D, Allen R, Kohnen R, et al. Loss of response during long-term treatment of restless legs syndrome: guidelines approved by the International Restless Legs Syndrome Study Group for use in clinical trials. Sleep Med. 2010; 11: 956-957.
16. Högl B, Garcia-Borreguero D, Trenkwalder C, et al. Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome. Sleep Med. 2011; 12: 351-360.
17. Trenkwalder C, Hogl B, Benes H, Kohnen R. Augmentation in restless legs syndrome is associated with low ferritin. Sleep Med. 2008; 9: 572-574.
18. Winkelman JW, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med. 2004; 5: 9-14.
19. Silber MH, Girish M, Izurieta R. Pramipexole in the management of restless legs syndrome: an extended study. Sleep. 2003; 26: 819-821.
20. Allen RP, Ondo WG, Ball E, et al. Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample. Sleep Med. 2011; 12: 431-39.
21. Silver N, Allen RP, Senerth J, Earley CJ. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Med. 2011; 12: 440-444.